MIT team develops simple, less painful diagnostic test for multiple myeloma using microfluidic chip and conventional blood sample.
In this review of the role of bortezomib in the treatment of multiple myeloma, the researchers explain what nurses need to watch for in patients taking this drug.
Carfilzomib significantly prolonged overall survival compared with bortezomib in patients with relapsed or refractory multiple myeloma.
Younger and usual adult body mass index (BMI) may be linked to increased risk for developing multiple myeloma, research indicates.
Blood test combined with medical status information predicts stem cell transplant success in patients with MDS.
Bendamustine, bortezomib, and dexamethasone is efficacious and tolerable as first-line therapy for patients with myeloma ineligible to receive high-dose therapy.
Results are presented from the phase 3 ENDEAVOR trial, which demonstrated the effect of carfilzomib plus dexamethasone (Kd) vs bortezomib plus dexamathasone (Vd) on risk of disease progression or death in patients with relapsed or refractory multiple myeloma.
A pooled analysis confirms the role of upfront autologous HCT as the standard approach for all young patients with multiple myeloma.
In this study, maintenance therapy with bortezomib plus thalidomide was compared with thalidomide alone or interferon alfa-2b alone in patients with newly diagnosed symptomatic multiple myeloma. Study findings demonstrate an impact on progression-free survival.
Researchers sought to determine the influence of obesity on the transformation of MGUS, an asymptomatic plasma cell neoplasm, to multiple myeloma.
Investigators found black patients with multiple myeloma are less likely to use newer, more advanced treatments such as autologous HSCT or bortezumib, and explored factors contributing to this as well as the impact on this population.
Researchers investigated whether VRd, which has demonstrated significant efficacy in newly diagnosed multiple myeloma, would improve outcomes in patients with previously untreated myeloma who are not planned for immediate ASCT.
Researchers report on an evaluation of the safety and preliminary efficacy of the HDAC6-selective inhibitor ricolinostat in combination with standard proteasome inhibitor therapy for relapsed or refractory multiple myeloma.
Results from a phase 3 trial comparing a 12-week dosing interval with the standard 4-week dosing interval of zoledronic acid to reduce the incidence of skeletal-related events and pain in patients with bone metastases.
Selinexor in combination with low dose dexamethasone is active in heavily pretreated patients with refractory multiple myeloma.
The combination of bendamustine, lenalidomide, and dexamethasone was highly active as second-line treatment for relapsed/refractory multiple myeloma.
A study presented at 2016 ASH annual meeting demonstrated that the combination of elotuzumab, lenalidomide, and dexamethasone has potential in patients with high-risk smoldering multiple myeloma, a population that would otherwise not receive treatment.
A study presented at the 2016 Annual Meeting of ASH assessed the impact of additional interventions on progression-free survival in patients with multiple myeloma.
Administration of beta blockers in patients with newly diagnosed multiple myeloma may be associated with a reduced risk of cancer-specific death.
Thalidomide and lenalidomide are equivalent with respect to survival outcomes in patients with multiple myeloma.
The US FDA has granted approval for additional indications for daratumumab for the treatment of patients with multiple myeloma who have received prior therapies.
A panel of International Myeloma Working Group members presents their review of current data on the potential host-, disease-, and treatment-related risk factors associated with the development of second primary malignancies in patients with multiple myeloma.
In this single-center, open-label, phase 2b trial, researchers determined if adding vorinostat to lenadolimide and dexamethasome would improve outcomes for patients with multiple myeloma refractory to lenalidomide.
In this study, researchers sought to improve the safety of panobinostat plus bortezomib and dexamethasone for relapsed or relapsed and refractory multiple myeloma.
Amgen talks about its collaboration with Janssen Biotech Inc on clinical trials that assess the combination of carfilzomib (Kyprolis) with daratumumab (Darzalex) in patients with multiple myeloma.
Results of this data analysis demonstrate the relationship between treatment facility volume and all-cause mortality among patients with multiple myeloma.
The phase 3 PANORAMA 1 trial previously demonstrated that panobinostat plus bortezomib and dexamethasone significantly prolonged progression-free survival vs bortezomib and dexamethasone alone. Final overall survival analysis is presented.
Adding daratumumab to lenalidomide and dexamethasone significantly prolonged progression-free survival compared with lenalidomide plus dexamethasone alone in patients with relapsed or refractory multiple myeloma.
The combination of ixazomib and dexamethasone is clinically active and well tolerated in patients with relapsed multiple myeloma not refractory to bortezomib.
A longer duration of lenalidomide maintenance therapy after autologous HSCT may improve progression-free and overall survival in patients with multiple myeloma.
- Increased 5-Year Survival Rate Seen in NSCLC Subset Treated With Nivolumab
- Health Care Expansion Tied to Increased Rates of Surgical Treatment of Thyroid Cancer
- Including a PI3-Kinase Inhibitor with an PARP Inhibitor Improves Tumor Shrinkage in Patients with Resistant Ovarian Cancer
- JAK1, JAK2 Inhibition Improves Outcomes in Myeloproliferative Neoplasms, But More Is Needed
- Hormone Refractory Prostate Cancer Responds to Abiraterone Acetate in Some Cases
- Exercise, Psychological Interventions Better for Cancer Fatigue Than Medications
- ASCO Issues Global Guidance for HPV Vaccination for Cervical Cancer Prevention
- Discharge Events Improved With Standardized Inpatient Palliative Care Consultation
- Little Opposition to Early Palliative Care for Symptom Management in Pediatric Oncology
- Physical Activity Improves Outcomes for Patients with Breast Cancer and Survivors
- Low Acculturated Latina Women Reported Breast Cancer Treatment Experience Differently Than Other Groups
- Cost and Complication Rates Differ Among Early Breast Cancer Treatment Options
- PSA Screening Rates Level Off in United States
- CQGS Releases Standards for Surgical Care of Older Adults
- Radiation Protocol Deviations Linked to Worse Outcomes in Pediatric Brain Malignancy
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|